Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Lischalk

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Practical Radiation Oncology|November 20, 2023
Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) GlandsJoshua C Hurwitz, Jonathan Haas, Christopher Mendez, et al.
Journal of Neuro-Oncology|January 4, 2023
Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3Tanja Eichkorn, Jonathan W Lischalk, Juliane Hörner-Rieber, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 6, 2025
High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancerJoshua C Hurwitz, Jonathan A Haas, Vianca F Santos, et al.
Radiation Oncology (London, England)|March 4, 2024
High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapyJonathan W Lischalk, Astrid Sanchez, Vianca F Santos, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
Frontiers in Oncology|February 19, 2025
Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocolAkrita Bhatnagar, Monica Pernia Marin, Jonathan W Lischalk, et al.
Advances in Radiation Oncology|April 25, 2025
Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation TherapyJonathan W Lischalk, Vianca F Santos, Brianna Vizcaino, et al.
Clinical and Translational Radiation Oncology|December 9, 2024
Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factorsAnna Krämer, Laura Hahnemann, Fabian Schunn, et al.
International Journal of Radiation Oncology, Biology, Physics|December 15, 2020
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)Juliane Hörner-Rieber, Tobias Forster, Adriane Hommertgen, et al.
Frontiers in Oncology|February 4, 2021
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation TherapyMichael Carrasquilla, Michael L Creswell, Abigail N Pepin, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Practical Radiation Oncology|November 20, 2023
Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) GlandsJoshua C Hurwitz, Jonathan Haas, Christopher Mendez, et al.
Journal of Neuro-Oncology|January 4, 2023
Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3Tanja Eichkorn, Jonathan W Lischalk, Juliane Hörner-Rieber, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 6, 2025
High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancerJoshua C Hurwitz, Jonathan A Haas, Vianca F Santos, et al.
Radiation Oncology (London, England)|March 4, 2024
High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapyJonathan W Lischalk, Astrid Sanchez, Vianca F Santos, et al.
Frontiers in Oncology|April 18, 2022
Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate CancerMichael C Repka, Michael Creswell, Jonathan W Lischalk, et al.
Frontiers in Oncology|February 19, 2025
Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocolAkrita Bhatnagar, Monica Pernia Marin, Jonathan W Lischalk, et al.
Advances in Radiation Oncology|April 25, 2025
Screening Colonoscopy Association With Gastrointestinal Toxicity and Quality of Life After Prostate Stereotactic Body Radiation TherapyJonathan W Lischalk, Vianca F Santos, Brianna Vizcaino, et al.
Clinical and Translational Radiation Oncology|December 9, 2024
Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factorsAnna Krämer, Laura Hahnemann, Fabian Schunn, et al.
International Journal of Radiation Oncology, Biology, Physics|December 15, 2020
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)Juliane Hörner-Rieber, Tobias Forster, Adriane Hommertgen, et al.
Frontiers in Oncology|February 4, 2021
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation TherapyMichael Carrasquilla, Michael L Creswell, Abigail N Pepin, et al.
Pageof 7